Opko Health [OPK] vs Thermo Fisher [TMO] Detailed Stock Comparison
Opko Health
NASDAQ
Loading...
Thermo Fisher
NYSE
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Opko Health wins in 8 metrics, Thermo Fisher wins in 10 metrics, with 0 ties. Thermo Fisher appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Opko Health | Thermo Fisher | Better |
|---|---|---|---|
| P/E Ratio (TTM) | -17.13 | 28.17 | Opko Health |
| Price-to-Book Ratio | 0.82 | 3.64 | Opko Health |
| Debt-to-Equity Ratio | 30.51 | 69.62 | Opko Health |
| PEG Ratio | -4.72 | 4.96 | Opko Health |
| EV/EBITDA | -7.04 | 19.69 | Opko Health |
| Profit Margin (TTM) | -26.68% | 15.24% | Thermo Fisher |
| Operating Margin (TTM) | -38.25% | 17.84% | Thermo Fisher |
| EBITDA Margin (TTM) | N/A | 17.84% | N/A |
| Return on Equity | -13.16% | 13.42% | Thermo Fisher |
| Return on Assets (TTM) | -8.46% | 4.97% | Thermo Fisher |
| Free Cash Flow (TTM) | $-208.50M | $7.27B | Thermo Fisher |
| Dividend Yield | N/A | 0.31% | N/A |
| 1-Year Return | -12.42% | -17.51% | Opko Health |
| Price-to-Sales Ratio (TTM) | 1.64 | 4.26 | Opko Health |
| Enterprise Value | $1.22B | $213.03B | Thermo Fisher |
| EV/Revenue Ratio | 1.83 | 4.93 | Opko Health |
| Gross Profit Margin (TTM) | 31.50% | 40.61% | Thermo Fisher |
| Revenue per Share (TTM) | $1 | $114 | Thermo Fisher |
| Earnings per Share (Diluted) | $-0.26 | $17.31 | Thermo Fisher |
| Beta (Stock Volatility) | 1.19 | 0.75 | Thermo Fisher |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Opko Health vs Thermo Fisher Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Opko Health | 2.17% | 2.92% | 2.17% | 11.02% | -18.02% | -2.76% |
| Thermo Fisher | 3.36% | 2.25% | 16.93% | 24.85% | -6.64% | -4.32% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Opko Health | -12.42% | -38.96% | -57.78% | -87.65% | -35.62% | 271.05% |
| Thermo Fisher | -17.51% | -11.30% | 17.79% | 295.19% | 1,057.92% | 1,679.96% |
Performance & Financial Health Analysis: Opko Health vs Thermo Fisher
| Metric | OPK | TMO |
|---|---|---|
| Market Information | ||
| Market Cap | $1.09B | $184.10B |
| Market Cap Category | Small cap | Large cap |
| 10 Day Avg. Volume | 2,737,240 | 2,020,610 |
| 90 Day Avg. Volume | 2,757,943 | 2,900,827 |
| Last Close | $1.41 | $500.00 |
| 52 Week Range | $1.11 - $2.04 | $385.46 - $627.88 |
| % from 52W High | -30.88% | -20.37% |
| All-Time High | $19.20 (Jun 01, 2015) | $672.34 (Dec 27, 2021) |
| % from All-Time High | -92.66% | -25.63% |
| Growth Metrics | ||
| Quarterly Revenue Growth | -0.14% | 0.03% |
| Quarterly Earnings Growth | -0.14% | 0.05% |
| Financial Health | ||
| Profit Margin (TTM) | -0.27% | 0.15% |
| Operating Margin (TTM) | -0.38% | 0.18% |
| Return on Equity (TTM) | -0.13% | 0.13% |
| Debt to Equity (MRQ) | 30.51 | 69.62 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $1.66 | $133.77 |
| Cash per Share (MRQ) | $0.34 | $16.92 |
| Operating Cash Flow (TTM) | $-239,462,000 | $7.58B |
| Levered Free Cash Flow (TTM) | $-185,865,120 | $5.18B |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | 0.31% |
| Last 12-Month Dividend | N/A | $1.21 |
Valuation & Enterprise Metrics Analysis: Opko Health vs Thermo Fisher
| Metric | OPK | TMO |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | -17.13 | 28.17 |
| Forward P/E | -4.72 | 20.76 |
| PEG Ratio | -4.72 | 4.96 |
| Price to Sales (TTM) | 1.64 | 4.26 |
| Price to Book (MRQ) | 0.82 | 3.64 |
| Market Capitalization | ||
| Market Capitalization | $1.09B | $184.10B |
| Enterprise Value | $1.22B | $213.03B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 1.83 | 4.93 |
| Enterprise to EBITDA | -7.04 | 19.69 |
| Risk & Other Metrics | ||
| Beta | 1.19 | 0.75 |
| Book Value per Share (MRQ) | $1.66 | $133.77 |
Financial Statements Comparison: Opko Health vs Thermo Fisher
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | OPK | TMO |
|---|---|---|
| Revenue/Sales | $149.95M | $10.36B |
| Cost of Goods Sold | $107.33M | $6.13B |
| Gross Profit | $42.62M | $4.24B |
| Research & Development | $30.84M | $342.00M |
| Operating Income (EBIT) | $-67.17M | $1.82B |
| EBITDA | $-34.15M | $2.73B |
| Pre-Tax Income | $-73.37M | $1.62B |
| Income Tax | $-5.77M | $95.00M |
| Net Income (Profit) | $-67.61M | $1.51B |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | OPK | TMO |
|---|---|---|
| Cash & Equivalents | $436.00M | $4.13B |
| Total Current Assets | $737.60M | $23.38B |
| Total Current Liabilities | $295.86M | $13.17B |
| Long-Term Debt | $368.00M | $31.37B |
| Total Shareholders Equity | $1.31B | $49.49B |
| Retained Earnings | $-2.13B | $54.45B |
| Property, Plant & Equipment | $119.01M | N/A |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | OPK | TMO |
|---|---|---|
| Operating Cash Flow | $-13.76M | $2.15B |
| Capital Expenditures | $67,000 | $-350.00M |
| Free Cash Flow | $-37.75M | $361.00M |
| Debt Repayment | $-9.72M | $-838.00M |
| Common Stock Repurchase | $0 | $-2.00B |
Short Interest & Institutional Ownership Analysis
| Metric | OPK | TMO |
|---|---|---|
| Shares Short | 32.77M | 3.71M |
| Short Ratio | 13.42 | 1.14 |
| Short % of Float | 0.07% | 0.01% |
| Average Daily Volume (10 Day) | 2,737,240 | 2,020,610 |
| Average Daily Volume (90 Day) | 2,757,943 | 2,900,827 |
| Shares Outstanding | 671.55M | 380.77M |
| Float Shares | 376.11M | 376.76M |
| % Held by Insiders | 0.47% | 0.00% |
| % Held by Institutions | 0.26% | 0.92% |
Dividend Analysis & Yield Comparison: Opko Health vs Thermo Fisher
| Metric | OPK | TMO |
|---|---|---|
| Last 12-Month Dividend | N/A | $1.21 |
| Last 12-Month Dividend Yield | N/A | 0.31% |
| 3-Year Avg Annual Dividend | N/A | $1.33 |
| 3-Year Avg Dividend Yield | N/A | 0.07% |
| 3-Year Total Dividends | N/A | $3.99 |
| Ex-Dividend Date | N/A | Mar 14, 2025 |